Femasys Inc (FEMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Femasys Inc (FEMY) has a cash flow conversion efficiency ratio of -0.976x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.94 Million) by net assets ($4.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Femasys Inc worth for the company's overall valuation and market capitalisation.
Femasys Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Femasys Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Femasys Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Femasys Inc ranked by their cash flow conversion efficiency. Explore FEMY operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ntaw Holdings Ltd
AU:NTD
|
0.021x |
|
Welsbach Technology Metals Acquisition Corp
NASDAQ:WTMA
|
0.018x |
|
Trust Finance Indonesia Tbk
JK:TRUS
|
-0.188x |
|
Pivotree Inc
V:PVT
|
0.002x |
|
Castor Maritime Inc
NASDAQ:CTRM
|
0.011x |
|
Inception Growth Acquisition Ltd
NASDAQ:IGTA
|
0.109x |
|
Litium AB (publ)
ST:LITI
|
0.018x |
|
Alpine Summit Energy Partners Inc
NASDAQ:ALPS
|
0.022x |
Annual Cash Flow Conversion Efficiency for Femasys Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Femasys Inc from 2019 to 2025. View Femasys Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.87 Million | $-18.69 Million | -3.184x | +62.26% |
| 2024-12-31 | $2.30 Million | $-19.44 Million | -8.438x | -1272.75% |
| 2023-12-31 | $18.35 Million | $-11.28 Million | -0.615x | +12.70% |
| 2022-12-31 | $15.24 Million | $-10.73 Million | -0.704x | -133.77% |
| 2021-12-31 | $26.33 Million | $-7.93 Million | -0.301x | +78.46% |
| 2020-12-31 | $3.53 Million | $-4.93 Million | -1.398x | -676.44% |
| 2019-12-31 | $-45.37 Million | $-11.01 Million | 0.243x | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal pat… Read more